BlueRiver Acquisition (NYSE:BLUA) & Delcath Systems (NASDAQ:DCTH) Critical Survey

BlueRiver Acquisition (NYSE:BLUA) and Delcath Systems (NASDAQ:DCTH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability and dividends.

Profitability

This table compares BlueRiver Acquisition and Delcath Systems’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BlueRiver Acquisition	N/A	N/A	-25.55%
Delcath Systems	-2,308.86%	-563.60%	-111.13%

Valuation and Earnings

This table compares BlueRiver Acquisition and Delcath Systems’ gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BlueRiver Acquisition	N/A	N/A	-$5.28 million	N/A	N/A
Delcath Systems	$2.07 million	65.14	-$47.68 million	($2.97)	-1.78

BlueRiver Acquisition has higher earnings, but lower revenue than Delcath Systems.

Analyst Ratings

This is a breakdown of recent ratings and target prices for BlueRiver Acquisition and Delcath Systems, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BlueRiver Acquisition	0	0	0	0	N/A
Delcath Systems	0	0	4	0	3.00

Delcath Systems has a consensus target price of $18.50, suggesting a potential upside of 253.73%. Given Delcath Systems’ higher probable upside, analysts clearly believe Delcath Systems is more favorable than BlueRiver Acquisition.

Insider and Institutional Ownership

22.3% of BlueRiver Acquisition shares are held by institutional investors. Comparatively, 61.1% of Delcath Systems shares are held by institutional investors. 79.0% of BlueRiver Acquisition shares are held by company insiders. Comparatively, 17.9% of Delcath Systems shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

BlueRiver Acquisition beats Delcath Systems on 5 of the 9 factors compared between the two stocks.

About BlueRiver Acquisition

BlueRiver Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to identify business opportunities in the field of technology, media, telecom, and entertainment industries. The company was incorporated in 2020 and is based in San Antonio, Texas.

About Delcath Systems

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.